Out of touch or on the money: Do the clinical objectives of addiction treatment coincide with economic evaluation results?

Dismuke, Clara E.; French, Michael T.; Salomé, Helena J.; Foss, Mark A.; Scott, Chris K.; Dennis, Michael L.

doi:10.1016/j.jsat.2004.08.005

Cited by 17 publications

(12 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Avoided criminal activity accounted for more than half of the estimated benefits in almost all cost-benefit studies of drug abuse treatment (McCollister & French, 2003). These measures of societal costs used in cost-benefit studies may not be significantly correlated with the clinical objectives of treatment, however (Dismuke et al, 2004). As a result, the cost-benefit method may not be very well suited to economic evaluations of alternative treatments.…”

Section: Cost-effectivenessmentioning

confidence: 99%

Outcomes and costs of matching the intensity of dual-diagnosis treatment to patients' symptom severity

Chen¹,

Barnett

Sempel

et al. 2006

Journal of Substance Abuse Treatment

View full text Add to dashboard Cite

Section: Cost-effectivenessmentioning

confidence: 99%

Outcomes and costs of matching the intensity of dual-diagnosis treatment to patients' symptom severity

Chen¹,

Barnett

Sempel

et al. 2006

Journal of Substance Abuse Treatment

View full text Add to dashboard Cite

“…The addiction treatment system is unique in that it is largely separate from the medical and psychiatric care delivery systems, and nicotine dependence tends to be ignored in all three of these systems. Integration of treatment could result in significant improvement in both medical, psychiatric and addiction outcomes and save costs, and could thus have far reaching implications for public health (Ray, Mertens, & Weisner, 2007; Dismuke et al, 2004, McLellan, Lewis, O'Brien, & Kelber, 2000). …”

Section: Discussionmentioning

confidence: 99%

Medical and Mental Health Status among Drug Dependent Patients Participating in a Smoking Cessation Treatment Study

Lima¹,

Reid²,

Smith³

et al. 2009

Journal of Drug Issues

View full text Add to dashboard Cite

Substance Abusers have a large number of medical and psychiatric problems, and 70-90% are smokers. The aim of this analysis was to examine the prevalence and correlates of medical and psychiatric problems in this sample of drug dependent patients who were participants in a multisite study of smoking cessation interventions while engaged in substance abuse treatment. Descriptive analyses showed at baseline, 72.8% of participants had at least one medical problem and 64.1% had at least one psychiatric diagnosis. Medical problems correlated strongly with age, smoking severity, and pack-years; Psychiatric problems correlated with gender and ethnicity. Smoking cessation treatment was associated with a moderate reduction in the ASI Medical composite score. More research is needed on the possible effects of combined treatment of substance abuse and concurrent medical and psychiatric problems. Offering smoking cessation in conjunction with primary care may be a way to address the health needs of this population.

show abstract

“…There is strong evidence that SATs are effective in lowering abuse of various substances over relatively long periods of time (McClellan et al, 1996; Simpson et al, 2002). Crime reductions, however, account for much of the economic benefits of SAT (French et al 2002; McCollister and French 2003; Dismuke et al 2004; Sindelar et al 2004). Types of SAT vary.…”

Section: Econometrics For Individualized Comparative Effectivenessmentioning

confidence: 99%

Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care

Basu

2011

Journal of Health Economics

View full text Add to dashboard Cite

The United States aspires to use information from comparative effectiveness research (CER) to reduce waste and contain costs without instituting a formal rationing mechanism or compromising patient or physician autonomy with regard to treatment choices. With such ambitious goals, traditional combinations of research designs and analytical methods used in CER may lead to disappointing results. In this paper, I study how alternate regimes of comparative effectiveness information help shape the marginal benefits (demand) curve in the population and how such perceived demand curves impact decision-making at the individual patient level and welfare at the societal level. I highlight the need to individualize comparative effectiveness research in order to generate the true (normative) demand curve for treatments. I discuss methodological principles that guide research designs for such studies. Using an example of the comparative effect of substance abuse treatments on crime, I use novel econometric methods to salvage individualized information from an existing dataset.

show abstract

Out of touch or on the money: Do the clinical objectives of addiction treatment coincide with economic evaluation results?

Cited by 17 publications

References 42 publications

Outcomes and costs of matching the intensity of dual-diagnosis treatment to patients' symptom severity

Outcomes and costs of matching the intensity of dual-diagnosis treatment to patients' symptom severity

Medical and Mental Health Status among Drug Dependent Patients Participating in a Smoking Cessation Treatment Study

Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care

Contact Info

Product

Resources

About